[DRNA] Dicerna Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 65.71 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.2 Change: 0.15 (4.92%)
Ext. hours: Change: 0 (0%)

chart DRNA

Refresh chart

Strongest Trends Summary For DRNA

DRNA is in the long-term up 326% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company?s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Ki

Fundamental Ratios
Shares Outstanding20.73 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.76 Price/Cash Per Share0.75
Price/Free Cash Flow-1.79 ROA-55.23% ROE-59.06% ROI
Current Ratio14.81 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities7.07 M Cash From Operating Activities-10.65 M Gross Profit
Net Profit-14.08 M Operating Profit-14.14 M Total Assets92.75 M Total Current Assets89.09 M
Total Current Liabilities6.02 M Total Debt Total Liabilities6.02 M Total Revenue
Technical Data
High 52 week15.9 Low 52 week9.67 Last close15 Last change2.25%
RSI55.63 Average true range0.82 Beta1.5 Volume169.43 K
Simple moving average 20 days3.8% Simple moving average 50 days5.69% Simple moving average 200 days13.6%
Performance Data
Performance Week7.53% Performance Month4.68% Performance Quart0.2% Performance Half3.09%
Performance Year13.38% Performance Year-to-date40.32% Volatility daily2.33% Volatility weekly5.21%
Volatility monthly10.69% Volatility yearly37.02% Relative Volume366.28% Average Volume405.27 K
New High New Low

News

2020-06-01 16:30:00 | Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-05-26 16:05:00 | Dicerna to Participate in Jefferies Virtual Global Healthcare Conference

2020-05-18 06:29:41 | Dicerna Pharmaceuticals, Inc. NASDAQ:DRNA Analysts Are Way More Bearish Than They Used To Be

2020-05-12 16:05:00 | Dicerna to Present at Upcoming May Investor Conferences

2020-05-10 22:39:07 | Were Hedge Funds Right About Dicerna Pharmaceuticals Inc DRNA?

2020-05-10 09:23:10 | Dicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

2020-05-09 16:31:04 | Dicerna Pharmaceuticals Inc DRNA Q1 2020 Earnings Call Transcript

2020-05-08 19:20:06 | Edited Transcript of DRNA earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-08 07:59:45 | The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

2020-05-07 18:45:10 | Dicerna Pharmaceuticals DRNA Reports Q1 Loss, Misses Revenue Estimates

2020-05-07 16:05:00 | Dicerna Announces First Quarter 2020 Financial Results and Provides a Business Update

2020-05-07 16:01:00 | Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer

2020-05-07 14:59:31 | 11 Small-Cap Stocks Analysts Love the Most

2020-05-01 16:30:00 | Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-30 16:05:00 | Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020

2020-04-29 07:36:15 | We're Not Worried About Dicerna Pharmaceuticals's NASDAQ:DRNA Cash Burn

2020-04-08 06:00:00 | Biotech vet Gilman's startup earns $190M-plus in Roche deal

2020-04-08 06:00:00 | Biotech vet Gilman's startup earns $190M-plus in Roche deal

2020-04-06 18:26:17 | Alnylam, Dicerna Join Forces to Take on Arrowhead

2020-04-06 10:30:48 | Former gene-silencing rivals bury the hatchet with new partnership

2020-04-06 07:00:00 | Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

2020-04-01 16:30:00 | Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-03-31 07:30:00 | Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan

2020-03-26 16:05:00 | Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic

2020-03-23 18:23:00 | Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals

2020-03-19 07:37:15 | The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

2020-03-18 16:05:00 | Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

2020-03-09 13:25:40 | Edited Transcript of DRNA earnings conference call or presentation 27-Feb-20 9:30pm GMT

2020-03-02 16:30:00 | Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-02-29 08:53:36 | Earnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

2020-02-27 18:25:11 | Dicerna Pharmaceuticals DRNA Reports Q4 Loss, Lags Revenue Estimates

2020-02-27 16:05:00 | Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

2020-02-20 16:05:00 | Dicerna™ to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020

2020-02-18 16:05:00 | Dicerna™ to Present at Upcoming Investor Conferences

2020-02-10 07:30:00 | Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors

2020-02-03 16:30:00 | Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-01-29 12:45:39 | 3 Charts Suggest Micro-Cap Stocks Are Headed Higher

2020-01-17 17:40:00 | Pharma and Biotech Aren’t Worried About Democratic Candidates’ Attacks Against Drugmakers

2020-01-02 16:30:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2020-01-02 07:30:00 | Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

2020-01-01 18:21:17 | Dow Jones Futures Signal Stock Market Gains To Start 2020: Tesla Deliveries Loom; Google, Disney Test Key Support

2020-01-01 07:40:20 | We've made it to 2020. These are the top business issues to look for in the new year

2019-12-19 07:30:00 | Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection

2019-12-18 11:03:04 | Dicerna's DRNA A1AT Candidate Gets Orphan Drug Tag in EU

2019-12-17 16:12:23 | Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails

2019-12-17 07:30:00 | Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

2019-12-17 06:00:00 | Atlas, MPM, Partners funnel $49M into a new gene-silencing startup

2019-12-16 08:00:00 | Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

2019-12-15 08:46:37 | The Dicerna Pharmaceuticals NASDAQ:DRNA Share Price Has Soared 805%, Delighting Many Shareholders

2019-12-08 15:46:38 | Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc DRNA